Nitrates for acute heart failure syndromes.

Area of Science:

• Cardiology
• Pharmacology
• Critical Care Medicine

Background:

• Acute heart failure syndromes (AHFS) are typically managed with diuretics, vasodilators, and inotropes.
• Nitrates have a history of use in AHFS, with small studies suggesting potential benefits.
• This review aimed to assess the clinical effectiveness and safety of nitrate vasodilators in AHFS management.

Purpose of the Study:

• To quantify the impact of different nitrate preparations (isosorbide dinitrate, nitroglycerin) and administration routes on clinical outcomes in AHFS.
• To evaluate the safety and tolerability of nitrates when used in AHFS treatment.
• To synthesize evidence from randomized controlled trials on nitrate therapy for AHFS.

Main Methods:

• Systematic review of randomized controlled trials identified through comprehensive database searches (CENTRAL, MEDLINE, EMBASE) and trial registers.
• Inclusion criteria focused on adult patients with AHFS, comparing nitrates against alternative interventions (e.g., frusemide, morphine, nesiritide, placebo).
• Data extraction and quality assessment were performed independently by two authors, using standardized methods for effect size calculation (MD, OR, 95% CI) and risk of bias evaluation.

Main Results:

• Four studies involving 634 participants met the inclusion criteria, with varying patient populations regarding acute myocardial infarction.
• No significant difference was found in symptom relief rapidity or key hemodynamic variables (SBP, DBP, heart rate, PAOP, CO) between nitrates and alternative interventions.
• One study indicated a higher incidence of adverse events with nitroglycerin compared to placebo after three hours; overall evidence quality was limited by few, low-quality studies.

Conclusions:

• Nitrate vasodilator therapy does not appear to offer significant advantages over alternative interventions for symptom relief or hemodynamic improvement in AHFS.
• While nitrates might be associated with fewer adverse effects than placebo in the short term, robust conclusions are hindered by limited, low-quality evidence.
• Further high-quality research is needed to definitively establish the role and safety of nitrates in the management of acute heart failure syndromes.